On November 4, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for cancer and autoimmune diseases, reported that it has completed enrollment in its global Phase 1/2 ABILITY-1 study of MDNA11. The Company will host a live key opinion leaders (KOL) webinar on November 10, 2026 from 9:00 a.m. to 10:00 a.m. Eastern Standard Time, to discuss updated data from the study.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously announced on October 5, 2026, updated data from ABILITY-1 will be presented by Prof. Paolo Ascierto, during an oral session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting on November 7th, 2026. The abstract was selected as one of the meeting’s Top 150 Abstracts.

MDNA11 is an investigational, long-acting IL-2 Superkine designed to activate and expand cancer-fighting immune cells. ABILITY-1 is evaluating MDNA11 both as a monotherapy and in combination with Merck’s KEYTRUDA (pembrolizumab). Overall, a total of 152 patients from Canada, US, Australia, Europe and South Korea were enrolled in this global study.

"Achieving our target enrollment in ABILITY-1 is an important milestone for the development of MDNA11 as we demonstrate the potential benefits of an engineered beta-enhanced IL-2 Superkine," said Fahar Merchant, PhD, President and Chief Executive Officer of Medicenna. "We believe MDNA11 has the potential to expand treatment options for patients with advanced cancers where significant unmet needs remain. ABILITY-1 is helping us define its potential role both as a standalone therapy and in combination with checkpoint inhibitors, and guide the next stage of clinical development. We are grateful to the patients, their families, physicians and clinical teams for their enthusiasm to achieve our target enrollment. We look forward to presenting the updated data at SITC (Free SITC Whitepaper) 2026 on November 7th and discussing the findings during our KOL webinar on November 10 th."

The webinar will feature Medicenna’s management team, Dr. Hussein A. Tawbi, MD, PhD, Professor of Melanoma Medical Oncology and Director of Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center, and Dr. André Mansinho, MD, MSc, a principal investigator in the Phase 1/2 ABILITY-1 study. Dr. Mansinho is the Director of Clinical Research at START Lisbon, Portugal, and a clinical researcher at the Gulbenkian Institute for Molecular Medicine (GIMM).

Medicenna KOL Webinar – Event Details

Date: November 10, 2026
Time: 9:00 a.m. – 10:00 a.m. EST
Format: Live Webinar with Q&A

Registration: Participants can register using this link: View Source A replay will be available on Medicenna’s website following the event.

About Dr. Hussein A. Tawbi, MD, PhD

Dr. Hussein A. Tawbi is a Professor of Melanoma Medical Oncology and Director of Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center in Houston, Texas. He also serves as Director of the Immuno-Oncology Clinical Drug Development Program and Co-Leader of MD Anderson’s Melanoma Moon Shot. He also co-founded and co-directs the Andrew M. McDougall Brain Metastasis Clinic and Research Program. Dr. Tawbi specializes in melanoma, immuno-oncology and the clinical development of innovative cancer therapeutics, with particular expertise in immune checkpoint inhibitors, treatment resistance and melanoma brain metastases. He has served as principal investigator on numerous clinical trials evaluating novel immunotherapies and combination treatment strategies and has made significant contributions to advancing personalized approaches to cancer treatment. Dr Tawbi has been a recipient of numerous honors, including Irwin H. Krakoff Award for Excellence in Clinical Research, The Otis W. and Pearl L. Walters Faculty Achievement Award in Clinical Research and MD Anderson President’s Award for Faculty Excellence. Dr. Tawbi has over 180 publications in high impact journals including the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Nature, Science, Nature Medicine among others. He is Co-Chair of the SITC (Free SITC Whitepaper) PD-1 Resistance Committee and in 2020 he was appointed to the President’s Council of Advisors on Science and Technology.

Dr. Tawbi obtained his MD in 2001 from the American University of Beirut, Beirut, Lebanon and completed his training in Internal Medicine and Hematology/Oncology at the University of Pittsburgh His clinical training was coupled with a PhD degree in Clinical and Translational Science.

About Dr. André Mansinho, MD, MSc

Dr. André Mansinho is Director of Clinical Research at START Lisbon, Portugal, and a clinical researcher at the Gulbenkian Institute for Molecular Medicine (GIMM). He earned his Integrated Master’s Degree in Medicine from NOVA Medical School – Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, in 2011. Following his medical studies, he completed his general medical residency at Centro Hospitalar Lisboa Ocidental and his residency in Medical Oncology at Centro Hospitalar Lisboa Norte. He is also an invited Assistant Professor at the Faculty of Medicine, University of Lisbon, where he has been involved in teaching and academic activities in oncology.

Dr. Mansinho specializes in the clinical development of innovative cancer therapies, with particular expertise in early-phase clinical trials, precision medicine and the treatment of genitourinary, gastrointestinal and skin cancers. He completed a clinical research fellowship at START in 2017 and has participated in numerous international clinical trials evaluating novel oncology treatments, including immunotherapies and targeted therapies. He is a member of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) and the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), and has contributed to peer-reviewed scientific publications and oncology research.

About ABILITY-1

ABILITY-1 (NCT05086692) is an open-label, multicenter Phase 1/2 dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MDNA11 both alone and in combination with pembrolizumab, in patients with advanced solid tumors. Previously disclosed ABILITY-1 results showed an objective response rate (ORR) of 36% with MDNA11 monotherapy (n=14) and 43% with MDNA11 in combination with pembrolizumab (n=14), in patients treated in the second or third line or following resistance to checkpoint inhibitors for melanoma, endometrial and gastrointestinal cancers, as disclosed on February 13, 2026.

(Press release, Medicenna Therapeutics, NOV 4, 2026, View Source [SID1234674247])